Biomarker testing is crucial for personalized oncology care, aiding in risk stratification and treatment decisions, but faces challenges in uptake and education. Multistakeholder partnerships and ...

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...

When Ginny Mason was diagnosed with inflammatory breast cancer in 1994, she never once heard the word “biomarker.” “Back then, all you got was ER and PR [the estrogen receptor and progesterone ...

If conducted every year or every other year, the multi-cancer early detection blood test could help more people survive cancer, researchers reported Thursday in BMJ Open. Adobe stock/HealthDay May 9 ...

The global statistics are terrifying. Prostate cancer is the fourth most common cancer in all populations, the second most common cancer among men worldwide, and ranks first in Europe, where a third ...

Research from the University of Cambridge may be able to start a national screening programme for the common cancer ...

Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies.

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...

May 9 (UPI) --Blood tests could catch as many as half of cancers at an earlier, more treatable stage, a new study says. If conducted every year or every other year, the multi-cancer early detection ...